drugset
drugset / Trial / NCT05467761

Bioavailability Study of Psilocybin in Normal Adults

NCT05467761 ↗

Phase 1 Withdrawn University of Wisconsin, Madison TRYP Therapeutics · collab
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this research study is to compare an oral dose of psilocybin and an intravenous (IV) infusion of psilocybin to assess differences in how the drug is absorbed by the body, the psychedelic experience, and any side effects when taken by healthy adult participants. Participants can expect to be in the study for approximately 12 weeks.

Timeline

Start
2023-06
Primary completion
2024-03
Completion
2024-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 5 mg Oral
Subject Psilocybin Other / unclassified 25 mg Oral

Indications

No indication recorded.